4-硝基-1H-吡唑-3-甲酸甲酯 | 138786-86-4

• 物质功能分类: 医药中间体 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 4-硝基-1H-吡唑-3-甲酸甲酯
• 中文别名: 4-硝基-1H-PYRAIDE-3-甲酸甲酯；4-硝基-1H-吡唑-3-羧酸甲酯；4-硝基吡唑-3-甲酸甲酯
• 英文名称: methyl 4-nitro-1H-pyrazole-3-carboxylate
• 英文别名: 4-nitro-1H-pyrazole-3-carboxylic acid methyl ester；methyl 4-nitro-1H-pyrazole-5-carboxylate
• CAS: 138786-86-4
• 化学式: C₅H₅N₃O₄
• mdl: MFCD00475939
• 分子量: 171.112
• InChiKey: ARAFBUCGMOKZMI-UHFFFAOYSA-N

物化性质

• 沸点：
  363.2±22.0 °C(Predicted)
• 密度：
  1.545

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  101
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 危险等级：
  IRRITANT
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  存储条件：2～8℃，干燥处，密封保存。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Methyl 4-nitro-1h-pyrazole-3-carboxylate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Methyl 4-nitro-1h-pyrazole-3-carboxylate
CAS number: 138786-86-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C5H5N3O4
Molecular weight: 171.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-硝基-1H-吡唑-3-甲酸甲酯 在 5%-palladium/activated carbon 、 甲酸铵 、 三乙胺 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 水 、 异丙醇 为溶剂， 反应 13.0h， 生成 methyl 4-(2,6-dichlorobenzamido)-1H-pyrazole-3-carboxylate
  参考文献：
  名称：

  发现具有有效的体外和体内抗癌活性的新型细胞周期蛋白依赖性激酶（CDK）和组蛋白脱乙酰基酶（HDAC）双重抑制剂。

  摘要：

  在当前的研究中，我们报道了一系列针对组蛋白脱乙酰基酶（HDAC）和细胞周期蛋白依赖性激酶（CDK）的新型基于1-H-吡唑-3-羧酰胺的抑制剂。代表性化合物N-（4-（（（2-氨基苯基）氨基甲酰基）苄基）-4-（2,6-二氯苯甲酰胺基）-1H-吡唑-3-羧酰胺（7c）和N-（4-（2-（（ 2-氨基苯基）氨基）-2-氧代乙基）苯基）-4-（2,6-二氯苯甲酰胺基）-1H-吡唑-3-羧酰胺（14a）对5种固体癌细胞系具有有效的抗增殖活性，显示出优异的抑制活性HDAC2（IC50分别为0.25和0.24 nM）和CDK2（IC50分别为0.30和0.56 nM）。另外，化合物7c和14a显着抑制A375和H460细胞的迁移。进一步的研究表明，化合物7c和14a可以阻止G2 / M期的细胞周期并促进A375，HCT116，H460和Hela细胞，与细胞内活性氧（ROS）水平升高有关。更重要的是，化

  DOI：

  10.1016/j.ejmech.2020.112073
• 作为产物：
  描述：

  4-硝基吡唑-3-甲酸 以 甲醇 、 甲苯 为溶剂， 生成 4-硝基-1H-吡唑-3-甲酸甲酯
  参考文献：
  名称：

  PHARMACEUTICAL COMBINATIONS OF 1-CYCLOPROPYL-3- [3-(5-M0RPHOOLIN-4-YL-METHYL-1H-BENZOIMIDAZOL-2-YL)- LH-1-PYRAZOL-4-YL]- UREA

  摘要：

  该发明提供了一种辅助化合物和一种盐化合物的组合物，所述盐化合物为1-环丙基-3-[3-(5-吗啉-4-基甲基-1H-苯并咪唑-2-基)-1H-吡唑-4-基]-脲的盐，所述盐选自乳酸盐和柠檬酸盐及其混合物。还提供了所述盐的晶型形式，制备所述盐的方法以及它们在治疗癌症中的用途。该发明进一步提供了一种辅助化合物和根据PCT/GB2004/002824（WO 2005/002552）中定义的式（I）或式（I'）的化合物的组合物，或者其盐、溶剂化合物、互变异构体或N-氧化物，其中R1、E、A和M如权利要求中所定义。

  公开号：

  US20100055094A1
• 作为试剂：
  描述：

  4-硝基-1H-吡唑-3-甲酸甲酯 在 钯 氮气 、 4-硝基-1H-吡唑-3-甲酸甲酯 、 乙醇 、 氢气 作用下， 以 乙醇 为溶剂， 以to give 4-amino-1H-pyrazole-3-carboxylic acid methyl ester (0.883 Kg, 98.9%) as a purple solid的产率得到4-氨基-1H-吡唑-3-羧酸甲酯
  参考文献：
  名称：

  PHARMACEUTICAL COMBINATIONS

  摘要：

  本发明提供了公式（0）的辅助化合物和公式（I'）的化合物的组合物。此外，还提供了组成化合物的晶体形式，制备它们的方法以及它们在治疗癌症方面的用途。

  公开号：

  US20110159111A1

文献信息

• IRAK DEGRADERS AND USES THEREOF
  申请人：Kymera Therapeutics, Inc.

  公开号：US20190192668A1

  公开（公告）日：2019-06-27

  The present invention provides compounds, compositions thereof, and methods of using the same.

  本发明提供了化合物、其组合物以及使用这些化合物的方法。
• [EN] SUBSTITUTED 2-AZABICYCLO[3.1.1]HEPTANE AND 2-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS<br/>[FR] DÉRIVÉS DE 2-AZABICYCLO[3.1.1]HEPTANE ET DE 2-AZABICYCLO[3.2.1]OCTANE SUBSTITUÉS EN TANT QU'ANTAGONISTES DU RÉCEPTEUR DE L'OREXINE
  申请人：CHRONOS THERAPEUTICS LTD

  公开号：WO2019043407A1

  公开（公告）日：2019-03-07

  There is provided a compound of formula (I), wherein L1 to L3, R1 to R4, X, A and B have meanings given in the description, and pharmaceutically acceptable salts, solvates and prodrugs thereof, which compounds are useful as antagonists of the orexin-1 and orexin-2 receptors or as selective antagonists of the orexin-1 receptor, and thus, in particular, in the treatment or prevention of inter alia substance dependence, addiction, anxiety disorders, panic disorders, binge eating, compulsive disorders, impulse control disorders, cognitive impairment and Alzheimer's disease.

  提供一种化合物，其化学式为（I），其中L1至L3，R1至R4，X，A和B的含义如描述中所给，并且其药学上可接受的盐、溶剂合物和前药，这些化合物可用作促进睡眠素-1和促进睡眠素-2受体的拮抗剂或作为促进睡眠素-1受体的选择性拮抗剂，因此，特别适用于治疗或预防物质依赖、成瘾、焦虑障碍、恐慌障碍、暴饮暴食、强迫障碍、冲动控制障碍、认知障碍和阿尔茨海默病等疾病。
• Spirocyclic compounds
  申请人：Berk C. Scott

  公开号：US20070117824A1

  公开（公告）日：2007-05-24

  The present invention relates to a novel class of substituted spirocyclic compounds. These compounds can inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the compounds of the instant invention and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of these compounds in vivo.

  本发明涉及一类新型的取代螺环化合物。这些化合物可以抑制组蛋白去乙酰化酶，并适用于在选择性诱导终末分化、阻止肿瘤细胞生长和/或凋亡的过程中使用，从而抑制这些细胞的增殖。因此，本发明的化合物在治疗具有肿瘤特征的患者方面是有用的，这些肿瘤具有肿瘤细胞的增殖。本发明的化合物还可能在预防和治疗TRX介导的疾病方面有用，例如自身免疫、过敏和炎症性疾病，以及预防和/或治疗中枢神经系统（CNS）疾病，如神经退行性疾病。本发明还提供了包括本发明化合物的药物组合物和这些药物组合物的安全用药方案，这些方案易于遵循，并在体内产生这些化合物的治疗有效量。
• AROMATIC COMPOUND
  申请人：Mitsubishi Tanabe Pharma Corporation

  公开号：EP1956009A1

  公开（公告）日：2008-08-13

  An aromatic compound represented by the following formula or a pharmaceutically acceptable salt thereof: , wherein ring A is a heterocyclic ring, ring B is a carbocyclic ring, a heterocyclic ring etc., G1, G2, G3, G4 and G5 are CH or N, X is -NH-, -O-, -CH2-, etc., Y is - CH2-,-CO-,-SO2- etc., Z is a single bond, -CO-, -SO2-, -NH-, -O-, -S-, -CONH-,-SO2NH-, etc., R2 is hydrogen, alkyl, alkoxy, halogen, etc., and R3 is carbocyclic group, heterocyclic group, alkyl, etc., is useful as a controlling agent of the function of CCR4 useful for the treatment or therapy for bronchial asthma, atopic dermatitis, etc.

  以下公式表示的芳香族化合物或其药用可接受盐： 其中，环A是杂环，环B是碳环、杂环等，G1、G2、G3、G4和G5是CH或N，X是-NH-、-O-、-CH2-等，Y是-CH2-、-CO-、-SO2-等，Z是单键、-CO-、-SO2-、-NH-、-O-、-S-、-CONH-、-SO2NH-等，R2是氢、烷基、烷氧基、卤素等，R3是碳环组、杂环组、烷基等， 作为控制CCR4功能的调节剂，对治疗或治疗支气管哮喘、特应性皮炎等疾病很有用。
• ATR抑制剂及其在医药上的应用
  申请人：贝达药业股份有限公司

  公开号：CN112851668A

  公开（公告）日：2021-05-28

  本发明涉及式(I)所示的一种新型化合物，其具有ATR调节活性。本发明还涉及这些化合物的制备方法以及包含其的药物组合物。